Abstract：【Objective】 To investigate the clinical effect of maintenance therapy with low dose of apatinib after transcatheter arterial chemoembolization (TACE) for primary liver cancer. 【Methods】 A total of 90 patients with primary liver cancer in our hospital were randomly divided into the observation group and the control group with 45 cases each. Patients in both groups were treated with TACE,while the patients in the observation group received 250 mg of apatinib maintenance treatment after TACE. T lymphocyte subsets (CD3+,CD4+,CD8+,CD4+/CD8+) on 1 day before surgery and 4 weeks post-TACE,tumor objective response rate (ORR),progression-free survival,total survival and adverse reactions after 1,3,6 and 12 months of treatment were compared between the two groups. 【Results】 Four weeks after treatment,CD3+,CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group,and CD8+ was lower than that in the control group. The differences were statistically significant (all P<0.05). After 6 and 12 months of treatment,the ORR rate of the observation group was higher than that of the control group,and the difference was statistically significant (all P<0.05). The progression-free survival period was 6.6 months in the control group and 11.9 months in the observation group; The total survival period of the control group was 5.1 months,while the progression-free survival period of the observation group was 9.8 months; Kaplan-Meier method and Log-rank test showed that the progression-free survival and total survival of the observation group were longer than those of the control group,and the difference was statistically significant (both P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).【Conclusion】 The effect of maintenance therapy with low dose of apatinib after TACE for primary liver cancer is significant,which can improve the tumor remission rate and the immune function of patients,improve the progression-free survival and total survival,while the adverse reactions are controllable.
高梦佳, 王羽, 郭文伟, 翟亚鹏. 原发性肝癌TACE术后采用小剂量阿帕替尼维持治疗的疗效[J]. 医学临床研究, 2023, 40(4): 578-581.
GAO Meng-jia, WANG Yu, GUO Wen-wei, et al. Efficacy of Maintenance Therapy with Low Dose of Apatinib after TACE for Primary Liver Cancer. JOURNAL OF CLINICAL RESEARCH, 2023, 40(4): 578-581.
[1] 张稳稳,郑曦孜,郑小红,等.晚期原发性肝癌药物研究进展[J].中国医药导报,2019,16(33):28-31.
[2] 景钦东,刘海鹏,王斌儒,等.甲磺酸阿帕替尼治疗进展期胃癌的研究进展[J].中国临床药理学与治疗学,2019,24(10):1194-1200.
[3] EISENHAUER E A,THERASSE P,BOGAERTS J,et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[4] LI J,QIN S K,XU J M,et al. Randomized,double-blind,placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J].J Clin Oncol,2016,34(13):1448-1454.
[5] 徐林友,胡文锋.甲磺酸阿帕替尼治疗非小细胞肺癌临床疗效及安全性分析[J].山西医药杂志,2019,48(24):3095-3097.
[6] 崔建东,罗敏,李涛,等.阿帕替尼联合肝动脉化疗栓塞治疗中晚期肝癌的疗效及安全性分析[J].现代肿瘤医学,2019,27(14):2553-2556.
[7] 杨彦鸿,曹碧辉,陈德基.TACE联合索拉非尼或阿帕替尼治疗中晚期肝细胞癌[J].中国介入影像与治疗学,2019,16(12):735-740.
[8] 熊金芹,张帆,王卫星.阿帕替尼联合替吉奥治疗TACE术后的原发性肝癌的临床研究[J].中国医院药学杂志,2019,39(18):1876-1880.
[9] CHEN S G,YU W C,ZHANG K Z,et al. Comparison of the efficacy and safety of transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma[J].BMC Cancer,2018,18(1):1131.
[10] 刘元伟,刘传,张红军,等.TACE联合阿帕替尼对原发性肝癌患者免疫功能的影响[J].肿瘤药学,2018,8(6):943-946.
[11] 杨武,程明,于立江,等.多西他赛联合阿帕替尼对晚期食管癌患者免疫功能及生活质量影响[J].临床军医杂志,2018,46(11):1369-1370.
[12] 翁志成,彭建扬,吴伟达,等.阿帕替尼联合S-TACE治疗中晚期原发性肝癌的疗效及安全性评价[J].癌症进展,2019,17(22):2666-2669.
2023, Vol. 40 
